Phase 2 trial of crofelemer for the treatment of acute watery diarrhea
Napo Pharmaceuticals announced positive study results from its completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea. In the multicenter, randomized, placebo-controlled study, resolution of diarrhea was significantly higher in patients treated with crofelemer than in those given placebo.Crofelemer is an antisecretory agent extracted from the plant Croton lechleri. Crofelemer is also being investigated for the treatment of HIV-related diarrhea, diarrhea-predominant irritable bowel syndrome, acute infections/watery diarrhea, and pediatric diarrhea.
For more information call (415) 371-8300 or visit www.napopharma.com.